Show simple item record

dc.contributor.advisorNah, Hyun-Duck
dc.contributor.advisorTuncay, Orhan C.
dc.creatorMilewski, Michael Edward
dc.date.accessioned2020-10-27T15:27:55Z
dc.date.available2020-10-27T15:27:55Z
dc.date.issued2011
dc.identifier.other864884937
dc.identifier.urihttp://hdl.handle.net/20.500.12613/1922
dc.description.abstractAngiogenesis is a normal and vital process that occurs during growth and development. Repair of bony defects, whether in the craniofacial complex or the alveolus, require an alloplastic or xenoplastic bone graft with angiogenic potential. This angiogenic potential is derived from existing blood vessels adjacent to the graft site. Improving the endogenous angiogenic potential with a molecule would drastically improve the survival rate of the bone graft material. This study was conducted to test the hypothesis that specific stem cell lines treated with erythropoietin, a positive promoter of angiogenesis, may increase the erythropoietin receptor expression in-vitro. In addition, this study also evaluated the vascular branching in vitro of human umbilical vein-derived endothelial cells treated with erythropoietin in the matrigel assay. Human umbilical vein-derived endothelial cells were treated for seven days with four concentrations of erythropoietin and cellular branching was evaluated in the matrigel assay. human bone marrow-derived mesenchymal stem cells and multi-potent cord blood derived unrestricted stromal stem cells were treated for seven days with erythropoietin and erythropoietin receptor expression was evaluated via reverse transcriptase real time polymerase chain reaction and real time polymerase chain reaction assays. The results of this study indicate that: erythropoietin had no effect on human umbilical vein-derived endothelial cells in the matrigel assay from a qualitative perspective, after treating multi-potent cord blood derived unrestricted stromal stem cells cells for 7 days with erythropoietin, there was no statistically significant difference between treatment groups when compared to control, and after treating human bone marrow-derived mesenchymal stem cells cells for 7 days with erythropoietin, the 20 U/ml treatment group showed a statistically significant reduction of the erythropoietin receptor as compared to the control group.
dc.format.extent104 pages
dc.language.isoeng
dc.publisherTemple University. Libraries
dc.relation.ispartofTheses and Dissertations
dc.rightsIN COPYRIGHT- This Rights Statement can be used for an Item that is in copyright. Using this statement implies that the organization making this Item available has determined that the Item is in copyright and either is the rights-holder, has obtained permission from the rights-holder(s) to make their Work(s) available, or makes the Item available under an exception or limitation to copyright (including Fair Use) that entitles it to make the Item available.
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectBiology
dc.subjectPharmaceutical Sciences
dc.subjectAngiogenesis
dc.subjectErythropoietin
dc.subjectIn Vitro
dc.subjectStem Cells
dc.titleThe Angiogenic effect of Erythropoietin on Stem Cells In-Vitro
dc.typeText
dc.type.genreThesis/Dissertation
dc.contributor.committeememberTuncay, Orhan C.
dc.description.departmentBiology
dc.relation.doihttp://dx.doi.org/10.34944/dspace/1904
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.degreeM.S.
refterms.dateFOA2020-10-27T15:27:55Z


Files in this item

Thumbnail
Name:
Milewski_temple_0225M_10703.pdf
Size:
5.162Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record